
Green Zebras S.A.
Research and experimental development in natural sciences and engineering
Overview
Green Zebras is a technology company that develops formulations for functional food and active substance feed additives, leveraging its experience in human food products for the veterinary sector. The company is currently expanding its research and development activities in pharmaceutical veterinary medicine, seeking new candidates for companion animal medications. Their team collaborates with specialists in human and veterinary drug development, preclinical pharmacology, and in vivo studies.
Financials
Revenue history (in k)
Financial insight
- The statement flags a going concern risk. Szczegółowy opis okoliczności wskazujących na zagrożenie kontynuowania działalności zamieszczono w załączniku Informacje dodatkowe w punkcie 9. Informacje dotyczące kontynuowania działalności.
From the notes
| Current income tax (CIT due) | $0 | |
| Profit allocation | Loss to be covered | |
| Loans and borrowings | $43,413 | |
| Capital expenditure | $24,274 | |
| Foreign sales | 6.36% of revenue ($20,166) | |
| Receivables write-downs | $2,522 |
Filing timeliness
Financial statements were filed on time, on average 31 days early. All were audited by a statutory auditor.
- 202503/07/2026
- 202417/04/2025
- 202302/07/2024
- 202204/07/2023
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 9.60
- High
- PLN 9.60
- Low
- PLN 8.65
- Volume
- 2.81K
- Avg. vol.
- 408.2
- Market cap
- PLN 13.72M
- P/E ratio
- –
- EPS
- -PLN 1.29
- Shares outstanding
- 1.59M
- 52-week
- PLN 8.65 – 10.40
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLGRNZB00015
- Exchange
- NewConnect
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q3 2026 | USD 0.00 | USD -119.39k | USD -121.29k |
| Q2 2026 | USD 4.86k | USD -201.78k | USD -202.05k |
| Q1 2026 | USD 80.23k | USD -111.02k | USD -113.72k |
| Q4 2025 | USD 67.30k | USD -126.82k | USD -128.83k |
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Trademarks
The company holds 1 active trademark registered with the Polish Patent Office. The first mark was filed in 2023.
| Mark | Protected until | |
|---|---|---|
| VERY CALM ZEBRA | Nov 13, 2033 |
Authorized Representatives
Manner of representation
The company is represented by each member of the management board independently.
Supervisory board
Bank accounts
Registered as a VAT taxpayer on 2020-04-23.
48 1090 2590 0000 0001 6616 4401
04 2490 0005 0000 4530 3300 5812
96 1090 2590 0000 0001 6616 4119
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 57,154PLN 57,154 |
MSiG notices
| Publication date | Event | |
|---|---|---|
| Dec 11, 2023 | Commercial Companies Code notice | |
| Nov 10, 2023 | Bankruptcy notice | |
| Oct 18, 2023 | Shareholders' meeting convened |
Public aid
7 public aid cases recorded, with a total value of $45,106.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Aug 26, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Marszałek Województwa Dolnośląskiego | |
| Aug 6, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Dolnośląska Agencja Współpracy Gospodarczej sp. z o.o. | |
| Sep 29, 2023 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | –– | Prezydent Wrocławia |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Pikralida sp. z o.o. | $1,151,165.63 | pikralida.eu | ||
| Medicofarma Biotech S.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Globe Badania Kliniczne sp. z o.o. | $283,646.38 | globebadania.pl | ||
| F1 Pharma S.A. | $272,113.66 | f1pharma.pl | ||
| Bioscientia sp. z o.o. | $238,316.98 | bioscientia.pl | ||
| Pharma Trend sp. z o.o. | $231,255.29 | pharmatrend.pl | ||
| TCI sp. z o.o. | $218,471.87 | tci.pl | ||
| Countess Laboratories sp. z o.o. | $164,970.29 | countess.pl | ||
| Ti-Com sp. z o.o. | $157,549.77 | ticomglobal.com | ||
| SN Biotech Technologies sp. z o.o. + limited partnership | $144,861.78 | snbiotech.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-09-02 | Share capital increase (158,656.80 PLN → 165,781.80 PLN) | |
| 2025-11-21 | Share capital increase (132,781.80 PLN → 158,656.80 PLN) | |
| 2024-12-24 | PKD change (Removed: 01.28.Z, 20.42.Z, 71.20.B; Added: 10.91.Z, 10.92.Z, 21.20.Z) | |
| 2024-02-02 | Share capital increase (124,816.90 PLN → 132,781.80 PLN) | |
| 2023-10-09 | Share capital increase (120,930.00 PLN → 124,816.90 PLN) |
FAQ
Last updated: 2026-09-02